Mirador Capital Partners LP Purchases Shares of 2,980 CRISPR Therapeutics AG (NASDAQ:CRSP)

Mirador Capital Partners LP acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 2,980 shares of the company’s stock, valued at approximately $203,000.

Several other large investors also recently modified their holdings of CRSP. Blue Trust Inc. acquired a new position in CRISPR Therapeutics in the 4th quarter valued at about $32,000. Bourgeon Capital Management LLC lifted its holdings in CRISPR Therapeutics by 1,000.0% during the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock worth $34,000 after purchasing an additional 500 shares during the last quarter. Principal Securities Inc. bought a new stake in CRISPR Therapeutics in the 4th quarter valued at $41,000. NBC Securities Inc. grew its holdings in CRISPR Therapeutics by 257.6% in the 1st quarter. NBC Securities Inc. now owns 608 shares of the company’s stock valued at $41,000 after buying an additional 438 shares in the last quarter. Finally, TFC Financial Management Inc. increased its position in CRISPR Therapeutics by 3,400.0% during the 4th quarter. TFC Financial Management Inc. now owns 700 shares of the company’s stock worth $44,000 after buying an additional 680 shares during the period. 69.20% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

CRSP has been the subject of a number of recent research reports. Robert W. Baird boosted their target price on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a research report on Thursday, May 9th. JMP Securities restated a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, May 9th. Needham & Company LLC reiterated a “buy” rating and issued a $88.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, June 27th. Citigroup reduced their price target on CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating on the stock in a research report on Thursday, May 23rd. Finally, Barclays dropped their price objective on CRISPR Therapeutics from $80.00 to $67.00 and set an “equal weight” rating for the company in a report on Thursday, May 9th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics has an average rating of “Hold” and a consensus target price of $75.71.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $53.95 on Tuesday. CRISPR Therapeutics AG has a one year low of $37.55 and a one year high of $91.10. The company has a market cap of $4.58 billion, a price-to-earnings ratio of -19.83 and a beta of 1.70. The firm has a 50 day simple moving average of $56.69 and a 200 day simple moving average of $64.47.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.08). The firm had revenue of $0.50 million during the quarter, compared to the consensus estimate of $25.53 million. The business’s revenue was down 99.5% compared to the same quarter last year. During the same period last year, the firm earned ($0.67) EPS. As a group, analysts expect that CRISPR Therapeutics AG will post -5.51 EPS for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 19,582 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the transaction, the chief executive officer now owns 208,122 shares of the company’s stock, valued at $12,468,589.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Samarth Kulkarni sold 19,582 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the sale, the chief executive officer now directly owns 208,122 shares in the company, valued at $12,468,589.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $56.09, for a total value of $188,798.94. Following the transaction, the chief operating officer now directly owns 6,745 shares in the company, valued at $378,327.05. The disclosure for this sale can be found here. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.